Odipin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Odipin

Odipin is a prescription-only medication that contains the active ingredient Nifedipine. It is primarily used for its effects on blood pressure and heart circulation. This preparation is a synthetic organic compound and is chemically defined by the structure C17H18N2O6.


Quick Facts

Property Description
Active Ingredient Nifedipine
Forms Immediate-release capsule, extended-release tablet
Pharmacological Class Calcium-channel blocker (Dihydropyridine subclass)
General Purpose Antihypertensive and Antianginal
Route of Administration Oral

What Type of Medicine is Odipin (Nifedipine)?

Odipin belongs to the calcium-channel blocker (CCB) class of drugs, specifically known as a first-generation dihydropyridine. This classification reflects its mechanism of action: inhibiting the flow of calcium ions into certain muscle cells in the heart and blood vessel walls. The drug’s function defines it as a potent peripheral arterial vasodilator, designed to reduce resistance in the circulatory system. As a first-generation dihydropyridine, Nifedipine primarily targets the peripheral vascular system.


Composition and General Purpose

Odipin is a single-ingredient product featuring only Nifedipine. It is manufactured in two primary dosage forms for the oral route of administration: an immediate-release capsule and an extended-release tablet. Nifedipine is intended for managing conditions related to elevated resistance in blood vessels. The drug possesses an antihypertensive property, helping to lower high blood pressure, and an antianginal property, improving blood flow to the heart muscle.

What side effects are possible with Odipin?

Possible Side Effects and Safety Information

Odipin (Nifedipine) has an officially documented safety profile, with potential effects classified by regulatory authorities based on observed frequency during clinical use. These adverse reactions are categorized using standard regulatory terminology, such as Very Common, Common, and Uncommon.


Frequency-Classified Adverse Reactions

The most frequently reported effect is peripheral edema (swelling of the extremities), which is classified as Very Common (1 in 10 patients). Effects categorized as Common (1 in 100 to < 1 in 10 patients) often involve the Nervous System and Vascular System, and include headache, dizziness, and flushing. Within the Gastrointestinal System, constipation is commonly reported. Official labels note that certain vasodilatory effects, such as headache and flushing, may be more common at the start of treatment.


Serious Adverse Reactions and Safety Restrictions

Regulatory documents highlight specific serious adverse events. Immediate-release formulations of Nifedipine have been associated with a paradoxical increase in anginal symptoms or myocardial infarction, particularly shortly after administration. The medicine is formally contraindicated (must not be used) in patients with conditions such as cardiogenic shock or severe aortic stenosis.

Safety notes also apply to specific populations and conditions. Caution is recommended for use in patients with hepatic impairment (impaired liver function). Additionally, extended-release tablets are contraindicated in individuals with known severe gastrointestinal narrowing.

Overdose and Emergency Response

The official regulatory documentation for Odipin (Nifedipine) overdose strictly focuses on its severe effects on the cardiovascular system. Documented manifestations include excessive hypotension (a severe drop in blood pressure), which may be accompanied by heart rhythm abnormalities such as a slow heartbeat (bradycardia) or rapid heartbeat (reflex tachycardia). Additional systemic signs may include confusion, drowsiness, dizziness, nausea, and vomiting.

Overdose is classified as life-threatening due to the documented risk of severe outcomes, including cardiogenic shock, myocardial infarction (heart attack), and potential progression to multiple organ failure. Individuals with pre-existing conditions, such as congestive heart failure, or co-ingestion with other cardio-active drugs face an increased risk of a severe outcome.

Regulatory guidance mandates that individuals must seek immediate medical attention and contact a poison control center at once. Immediate action is required, and emergency services must be called if critical signs such as collapse, seizure, trouble breathing, or loss of consciousness are observed. The management described in official documentation is symptomatic and supportive, often involving procedures like the administration of IV calcium and vasopressors under continuous medical observation. Hospital monitoring may be required due to the effects of long-acting preparations.

Therapeutic Uses of Odipin

What Odipin Treats: Main Uses and Benefits


Odipin (Nifedipine) is commonly used across therapeutic domains involving restricted blood flow and heightened physiological activity, generally offering targeted supportive relief against these symptomatic patterns. The medicine is utilized to help manage high blood pressure and symptoms related to chest pain.

The primary therapeutic areas where Odipin is relevant include managing chronic high blood pressure (hypertension), providing support for symptoms of chest pain (angina)—specifically chronic stable angina and vasospastic angina—and managing peripheral vasospastic disorders such as Raynaud's phenomenon.

Managing Symptomatic Burden

This medication is applied in clinical settings marked by the necessity for sustained pressure reduction and managing symptoms related to vascular discomfort. For patients, this provides a foundational, long-term approach to blood pressure control, which may contribute to easing the overall strain on the circulatory system. This supportive role helps with managing symptoms that interfere with daily comfort. It helps ease the overall symptomatic load:

“The consistent use of this medication supports the patient's experience by assisting with the management of painful episodes and contributing to improved comfort during periods of heightened symptoms.”

It is relevant for managing symptom groups like pain, numbness, and coldness associated with vasospasm.


Quick Fact: Support for Vascular Symptoms

Area of Support Primary Benefit
Systemic Pressure Helps maintain blood pressure control, easing cardiovascular strain.
Anginal Symptoms Supports management of chest pain episodes, assisting with maintaining functional stability.
Peripheral Spasm Plays a role in managing acute, distressing manifestations of cold-induced attacks.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Odipin — Official Regulatory Information

Odipin (Nifedipine) use is strictly governed by regulatory labeling, which defines both eligible populations and specific exclusions.


Eligibility Scope

Classification Population or Condition
Allowed (Established) Adults (18 years and over) who meet no absolute restrictions.
Not Established/Recommended Children below 18 years (Safety and efficacy are not established). Pregnant and lactating women (Use is generally not recommended).

Absolute Non-Eligibility (Contraindications)

Odipin must not be used in patients with the following formally documented conditions:

  • Known hypersensitivity to Nifedipine or any other dihydropyridine compound.
  • Concomitant use of Rifampicin.
  • A diagnosis of cardiogenic shock.
  • Unstable angina or within one month of an acute myocardial infarction (in certain international labels).
  • Severe gastrointestinal obstruction or a Kock pouch (for extended-release forms).

Conditional Use and Restrictions

Use requires caution and monitoring in patients with impaired liver function or those with pre-existing conditions like severe hypotension or manifest heart failure. Immediate-release formulations are generally avoided in older patients due to documented safety concerns.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Odipin, which contains Nifedipine, has officially documented interaction patterns primarily concerning its metabolism and blood pressure effects. Co-administration with the strong enzyme inducer Rifampin is contraindicated by regulatory agencies, as it significantly reduces Nifedipine's systemic exposure and efficacy. Other substances that induce the CYP3A4 enzyme, such as certain antiepileptic medicines and the herbal product St. John's Wort, can also decrease plasma concentrations.

Conversely, strong CYP3A4 inhibitors, including specific antibiotics (like macrolides) and antifungals (like azoles), are documented to increase Nifedipine exposure by inhibiting its clearance. This same effect is noted with other calcium-channel blockers like Diltiazem and Verapamil.

Pharmacodynamic and Food Interactions

Interaction Type Interacting Substance Official Regulatory Outcome
Pharmacodynamic (Additive) Beta-Blockers & other Antihypertensives Risk of enhanced hypotensive effect
Food/Metabolic Grapefruit Juice Avoided; increases plasma concentration

Furthermore, the official label includes administration constraints: a 36-hour washout period is required if surgery involving high-dose Fentanyl is contemplated. Patients with hepatic impairment are also noted to have reduced clearance, resulting in increased systemic exposure.

Mechanism of Action

How Odipin Works

Odipin (Nifedipine) is a calcium channel blocker that modulates the vascular smooth muscle system through a targeted molecular cascade. Its primary action is the inhibition of L-type Voltage-Gated Calcium Channels (L-VGCCs) found on arterial cell membranes. By blocking the critical influx of calcium ions ( Ca^2+), the drug disrupts the excitation-contraction coupling pathway, preventing the molecular signaling required for smooth muscle tightening. This initiates peripheral vasodilation.

This widespread arterial relaxation fundamentally alters Vascular Tone Regulation throughout the body, reducing the total Systemic Vascular Resistance ( SVR). This systemic consequence directly reduces the afterload—the pressure the heart must pump against—while simultaneously increasing blood flow through the coronary vasculature. A physiological consequence inherent to this mechanism is the acute drop in pressure, which activates the body's baroreceptor reflex (an autonomic pathway). This regulatory feedback mechanism increases sympathetic outflow, resulting in reflex tachycardia that partially counteracts the decrease in arterial pressure.

Dosage and Administration Information

How to Use Odipin

Odipin (Nifedipine) is administered via the oral route and is available in two primary forms: an immediate-release (IR) capsule and an extended-release (ER) tablet. The specific formulation determines the required dosing frequency and administration conditions.


Administration Requirements and Frequency

Formulation Standard Frequency Administration Condition
IR Capsule Taken multiple times daily (e.g., three to four times a day). Can generally be taken with or without food.
ER Tablet Taken once daily, preferably at the same time each day. Must be swallowed whole; crushing or chewing compromises the controlled-release mechanism.

The ER tablet is designed to maintain a consistent release of medicine over 24 hours. Consequently, its structural integrity is essential for proper function, and the tablet's outer shell may be observed in the stool.


Standard Dosing and Adjustments

For most adult indications, therapy typically begins with a defined starting dose (e.g., 30 mg or 60 mg once daily for the ER tablet). Adjustments to the dosage, if necessary, are performed gradually, often at intervals of 7 to 14 days, until the desired maintenance range is reached. This process is standardized to manage drug levels over time.

Dosing involves careful monitoring and potential reduction when treating patients with hepatic impairment due to reduced clearance. Additionally, the consumption of grapefruit or grapefruit juice is avoided during treatment, as it can affect drug metabolism. If treatment is to be stopped, the dosage is gradually decreased rather than discontinued abruptly.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Odipin (Nifedipine)

Evidence for Essential Hypertension (Chronic High Blood Pressure)

The research into Odipin's role in the context of essential hypertension (chronic high blood pressure) is extensive. Studies explored outcomes monitoring physiological strain or stress and outcomes related to systemic or functional imbalance. This body of evidence primarily includes large-scale Randomized Controlled Trials (RCTs) and meta-analyses that have monitored adult populations with mild to severe high blood pressure over defined time intervals.

Studies reported measurements of changes in blood pressure values and observed patterns related to the rate at which treated groups achieved target pressure levels. Evidence derived from settings with varying symptom burdens indicates that while data show patterns related to blood pressure changes, there are limitations regarding the older, immediate-release formulation. Because some early data raised reports about rapid changes in blood pressure, regulatory documents predominantly reflect data derived from studies of the long-acting/extended-release forms for the study of long-term blood pressure patterns. Research remains limited for its application in pediatric populations.

Evidence for Chronic Stable and Vasospastic Angina

Odipin was studied for its use in two distinct types of chest pain. For chronic stable angina (chest pain related to effort), research explored short-term patient experiences through RCTs in adults. These studies monitored outcomes related to physical discomfort, such as the frequency of anginal episodes and the ability to exercise. Findings describe patterns observed in the studies, where measurements of the number of weekly chest pain episodes were tracked.

For vasospastic angina (caused by blood vessel spasms), the evidence primarily comes from controlled clinical trials focused on episodic or acute changes. Research examined how symptoms evolved in the observed populations, specifically looking at the recorded changes in the frequency of spasm-related attacks. Long-term outcomes data specifically for this type of angina are not fully established.

Evidence for Raynaud's Phenomenon

Odipin was evaluated in studies relevant in trials assessing short-term or episodic symptom patterns in individuals with Raynaud's phenomenon. The evidence base here is generally composed of systematic reviews and meta-analyses that combine data from smaller RCTs. Studies explored outcomes related to physical discomfort, specifically measuring the frequency and severity of vasospastic attacks and patient-reported outcomes describing perceived discomfort and pain. Research exploring short-term symptom changes highlights that follow-up durations were limited (often less than six months), meaning there is limited information for long-term outcomes regarding the sustained use of the drug for this condition.

Evidence Gaps and Areas of Research Uncertainty

A key limitation concerns the older, immediate-release formulation; its use has specific constraints due to safety patterns observed in earlier data; the most robust, long-term evidence applies specifically to the extended-release tablets. Data related to long-term effects are not fully established for indications like Raynaud's phenomenon, where follow-up durations were limited. Overall, research provides context but not individual predictions, and comparative evidence against certain newer treatments is lacking in some areas.

Key Studies & References Nifedipine Extended-Release Tablets, USP 30 mg - DailyMed (Official Labeling)

Frequently Asked Questions (FAQ)

Common questions about Odipin (FAQ)


Q: Is Odipin considered a medication that needs to be taken long-term?

Official product information states that Odipin is prescribed for conditions like essential hypertension and chronic stable angina, which generally require long-term management. Studies supporting the drug's use over defined time intervals primarily involve the extended-release formulation.

Q: Does Odipin have a known effect on weight, such as causing weight gain or loss?

Official safety documentation includes reports of both unusual weight gain or loss as observed effects. While not common, rapid weight gain is also noted in some safety data.

Q: Can taking Odipin cause issues with sleep or excessive drowsiness?

According to regulatory safety documents, excessive drowsiness or insomnia are not consistently reported as common side effects. However, some less common reports have mentioned feelings of sleepiness or unusual drowsiness.

Q: What is the official guidance on consuming alcohol while using Odipin?

Official regulatory sources indicate that consuming alcohol while on this medication may cause an additive effect in lowering blood pressure. This additive effect could potentially increase effects such as headache, dizziness, or fainting.

Q: Does Odipin pose any specific risks for people with existing kidney problems?

While official documentation primarily focuses on precautions for hepatic impairment (liver function), clinical literature suggests that renal function (kidney function) should be closely monitored. Patients with existing kidney problems may require careful oversight from their medical team.

Q: What is the recommended procedure if a dose of Odipin is missed?

Official dosing instructions state that if you realize you have missed a dose, you should take it if there is a significant amount of time before the next one. If it is almost time for your next scheduled dose, it is generally advised to skip the missed dose and continue with your regular schedule. It is generally advised not to double the dose to compensate for a skipped one.

Q: What are the symptoms if someone accidentally takes too much Odipin?

If too much Odipin is taken, symptoms may include severe dizziness, profound low blood pressure (shock), and significant changes to heart rhythm, such as a very slow or rapid heartbeat. Other effects can include confusion and vomiting.

Q: Is Odipin effective for treating a sudden spike in blood pressure (a hypertensive emergency)?

Regulatory guidance strictly contraindicates (forbids) the use of the immediate-release formulation for the acute or sudden reduction of high blood pressure. This is due to documented safety concerns regarding the risk of profound low blood pressure and acute heart issues. The extended-release form is also not used for emergency blood pressure management.

Q: Is Odipin considered to be addictive or habit-forming?

Official regulatory bodies do not classify the active ingredient in Odipin as a controlled substance. Therefore, it is generally not known to be addictive or habit-forming.

Q: Are there research findings that show how Odipin works in different racial or ethnic groups?

Studies have documented that there may be differences in how the drug is metabolized (processed by the body) among various racial and ethnic groups. These variations are often linked to genetic differences in enzymes, such as CYP3A4.

Q: How long do common side effects, like headache and fatigue, usually last when first starting Odipin?

According to official safety information, common effects like headache or flushing that occur when first starting treatment are often mild. These effects may subside within a few days or a couple of weeks as the body adjusts to the medicine.

Q: Can Odipin cause an upset stomach or abdominal pain?

Official safety data notes that effects on the Gastrointestinal System are possible. Reported effects include constipation (which is common), nausea, and general stomach discomfort or upset.

Q: What are the signs of a serious side effect or allergic reaction from Odipin?

Signs that could indicate a serious or allergic reaction include difficulty breathing or swallowing, swelling of the face, tongue, or lips, and the development of a rash. Other serious signs include fainting or jaundice (yellowing of the skin or eyes).

Q: Can Odipin interact with common over-the-counter pain relievers or cold medicines?

Official regulatory documents emphasize listing all medications, including over-the-counter (OTC) products, vitamins, and herbal supplements, when discussing treatment. This general advice is provided because of the possibility that other products may affect how Odipin is processed.

How should Odipin be stored and disposed of?

How to Store and Dispose of Odipin (Nifedipine)

Odipin must be stored according to official regulatory requirements to maintain its stability and effectiveness.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, generally 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Protection Keep the medicine protected from strong light and shielded from moisture and humidity.
Container Store in the original container, which must be kept tightly closed.
Safety Keep the medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Odipin should be disposed of properly. The drug take-back program is the preferred disposal method. If a take-back program is unavailable, mix the medicine with an undesirable substance (such as dirt or coffee grounds), place it in a sealed bag, and discard it in the household trash. The medication must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Odipin found in:

A-Z Index: